Blue Coast Research Center (Open) Protocol Summaries

INDICATION

AGE CRITERIA

DESCRIPTION

Atrial fibrillation

> 80 yrs old

A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes

Chronic Hearth Failure

18-85 yrs

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of JK07 in Adults With Chronic Heart Failure

COPD

40 to 80

A Randomized, Double-blind, Parallel Group, Multi-Center, Phase III study to assess the Efficacy of Budesonide, Glycopyrroniu,, and Formoterol Fumarate Metered Dose Inhaler relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

Chronic Hearth Failure

18 to 85

A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients with Chronic Heart Failure

Atrial fibrillation

Age 65-74 and CHA2DS2VASc ≥4
age ≥75 and CHA2DS2VASc ≥3

A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC)

Heart Failure

18 +

A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function Sponsor

Blue Coast Research Center (Upcoming) Protocol Summaries

INDICATION

AGE CRITERIA

DESCRIPTION

Atrial fibrillation

65 +

Phase 3 study to assess the efficacy and safety of asundexian with atrial fibrillation at risk for stroke who were deemed unsuitable to receive treatment with oral anticoagulants.

Elevated Lipoprotein

TBD

A Double-blind, Randomized, Placebo controlled, Multicentre Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in High-risk Participants with Elevated Lipoprotein(a)

ASCVD

≥18 years

Evaluating INClisiran as a soLUtion to improve LDL-C management and cloSe care gaps in an Inclusive ASCVD and ASCVD risk equivalent populatiON